Abstract Number: 2470 • 2017 ACR/ARHP Annual Meeting
Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg subcutaneously every 2 weeks…Abstract Number: 147 • 2017 ACR/ARHP Annual Meeting
Performance of Cardiovascular Risk Age and Vascular Age Estimations in Predicting Cardiovascular Events in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) patients are at high risk of cardiovascular disease (CVD). Risk algorithms for the general population lack precision when applied to RA…Abstract Number: 532 • 2017 ACR/ARHP Annual Meeting
Genetic Predictors of Iguratimod Clinical Response and Toxicity in Patients with Rheumatoid Arthritis
Background/Purpose: Iguratimod (IGU) is a novel DMARD in rheumatoid arthritis (RA). The purpose of this study was to identify genetic predictors of response and adverse…Abstract Number: 1456 • 2017 ACR/ARHP Annual Meeting
Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation
Background/Purpose: Despite the availability of immunosuppressive disease-modifying anti-rheumatic agents (DMARDs), many rheumatoid arthritis (RA) patients still fail to achieve remission. Fibroblast-like synoviocytes (FLS) are non-immunological…Abstract Number: 2471 • 2017 ACR/ARHP Annual Meeting
Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg subcutaneously [SC] every 2…Abstract Number: 101 • 2016 ACR/ARHP Annual Meeting
Rheumatology Care Utilization and Geographic Distance from Rheumatology Sites within the United States Veteran Affairs Health Care System
Background/Purpose: Within the Veteran Affairs (VA) health care system, there are often large geographic distances between patients and rheumatology providers. The purpose of this study…Abstract Number: 633 • 2016 ACR/ARHP Annual Meeting
High Similarity Between Ex-Vivo Inhibited Cytokine Profiling By Golimumab and Adalimumab As a Putative Explanation for Inferior Treatment Response to Golimumab after Adalimumab Failure in Rheumatoid Arthritis
Background/Purpose: Better prediction of treatment response to biologics in rheumatoid arthritis (RA) would contribute to optimal individualized treatment. Clinical data suggest that the response of…Abstract Number: 1617 • 2016 ACR/ARHP Annual Meeting
Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience both substantial fatigue and a decline in their health-related physical and emotional well-being. Sirukumab is a…Abstract Number: 2521 • 2016 ACR/ARHP Annual Meeting
Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Background/Purpose: Serum 14-3-3η is a mechanistic marker that is involved in the pathogenesis of RA and is a potent up-regulator of IL-6. We previously reported…Abstract Number: 119 • 2016 ACR/ARHP Annual Meeting
Impact of Socioeconomic Status on Disease Outcomes in Japanese Patients with Rheumatoid Arthritis Under the Japanese National Insurance System
Background/Purpose: Several studies showed lower socioeconomic status (SES) was associated with higher disease activity and lower quality of life (QOL) in patients with rheumatoid arthritis…Abstract Number: 954 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Background/Purpose: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases…Abstract Number: 1631 • 2016 ACR/ARHP Annual Meeting
Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 MOBILITY (NCT01061736) and TARGET (NCT01709578) studies, sarilumab (150 or 200 mg subcutaneously…Abstract Number: 2548 • 2016 ACR/ARHP Annual Meeting
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
Background/Purpose: Recent trial data from Mariette et al. investigating a single-dose 1g rituximab regimen as opposed to a double-dose 1g rituximab regimen in patients with…Abstract Number: 129 • 2016 ACR/ARHP Annual Meeting
Ultrasound Is More Reliable Than Inflammatory Parameters (ESR and CRP) to Evaluate Disease Activity in Rheumatoid Arthritis Patients on Tocilizumab Therapy
Background/Purpose: The goal of therapy of rheumatoid arthritis(RA) is to achieve a remission or at least low disease activity. Tocilizumab completely interrupt the effect of…Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting
Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 56
- Next Page »